HCT 116 ADAM17 Cell Line
Invented at Queen's University Belfast
- Datasheet
- References (2)
- Inventor Info
Info
| Catalogue Number | 153209 |
| Antigen/Gene or Protein Targets | mouse ADAM17 (TACE) |
| Parental Line | HCT 116 |
| Host | Human |
| Tissue | Colon |
| Disease Keywords | Colorectal cancer |
| Model | Knock-In |
| Relevance | Chemotherapy (5-fluorouracil) treatment has been shown to result in acute increases in transforming growth factor-α, amphiregulin, and heregulin ligand shedding in vitro and in vivo correlating with significantly increased ADAM-17 activity. Small interfering RNA–mediated silencing and pharmacologic inhibition confirmed that ADAM-17 was the principal ADAM involved in this prosurvival response. HCT 116 ADAM17 Cell Line showed that overexpression of ADAM-17 significantly decreases the effect of chemotherapy on tumor growth and apoptosis. |
| Production Details | HCT116 cells were cotransfected with 10 μg of a plasmid containing hemagglutinin (HA)-tagged full-length mouse ADAM-17 (HA-ADAM-17) and a construct expressing a puromycin resistance gene. Stably transfected cells were selected and maintained in medium supplemented with 1 μg/mL puromycin. |
| Conditional | No |
| Research Area | Cancer, Drug Discovery & Development |
| Growth/Phenotype Keywords | Invasion, migration |
| Recommended Growing Conditions | McCoy’s 5a Medium (GIBCO # 16600) + 10% FBS + 100 units/ml penicillin+ 100 μg/ml streptomycin |
| Notes | Offered under licence from the Spanish National Research Council (CSIC) |
| Cellosaurus ID | CVCL_HG03 |
References: 2 entries
Kyula et al. 2010. Clin Cancer Res. 16(13):3378-89. PMID: 20570921.
Chemotherapy-induced activation of ADAM-17: a novel mechanism of drug resistance in colorectal cancer.
Europe PMC ID: 20570921
Add a reference
References: 2 entries
Kyula et al. 2010. Clin Cancer Res. 16(13):3378-89. PMID: 20570921.
Chemotherapy-induced activation of ADAM-17: a novel mechanism of drug resistance in colorectal cancer.
Add a reference
